Floatz logo

Semaglutide

Diabetic Kidney Disease

Geisinger Clinicprotein_peptidePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Diabetic Kidney Disease cohort.

Asset / SponsorPhaseRating
Folic Acid
Fuling Central Hospital of Chongqing City
Phase 2/3BB
VALSARTAN
Columbia University
Phase 4BB
Spironolactone
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Phase 4BB
SIMVASTATIN
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3BB
Lisinopril
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3BB

View all 18 →

Same molecule, other indications

Semaglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
81 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →